Dyne Therapeutics (NASDAQ:DYN) Director Sells $508,510.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 24,100 shares of Dyne Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $21.10, for a total transaction of $508,510.00. Following the sale, the director owned 1,081,044 shares in the company, valued at $22,810,028.40. This represents a 2.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of DYN opened at $20.94 on Monday. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The stock has a market cap of $3.46 billion, a PE ratio of -6.50 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The firm has a fifty day moving average price of $18.45 and a 200 day moving average price of $18.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the business posted ($1.05) EPS. As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics in the 4th quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $84,000. Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday, May 15th. Morgan Stanley lowered their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.